Ovarian cancer is the most lethal gynaecological malignancy, largely because most cases are diagnosed at advanced stage. PARP inhibitors have transformed maintenance therapy for BRCA-mutated and HRD-positive disease, with significant improvements in progression-free survival. Antibody-drug conjugate development and novel immunotherapy combinations represent the frontier for platinum-resistant disease.
Loading articles...
